Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
復星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the "Announcement in Relation to the Approval for Drug Registration of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
22 January 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Announcement in Relation to the Approval for Drug Registration of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, the drug registration application for Norepinephrine Bitartrate Injection (the "**Drug**") of Jinzhou Avanc Pharmaceutical Co., Ltd.* (錦州奧鴻藥業有限責任公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the "**Company**"), has been approved by the National Medical Products Administration. The approved indication is for the restoration of blood pressure in acute hypotensive states.Also indicated as adjunctive therapy in cardiac arrest and for blood pressure maintenance after resuscitation from cardiac arrest.In shock due to hypovolemia, this product may be used as an adjunct to volume replacement to elevate blood pressure, temporarily maintain cerebral and coronary perfusion until volume restoration measures become effective.

II. Registration Information of the Drug

Generic Name: Norepinephrine Bitartrate Injection

Dosage Form: Injection

Strength: 4ml:8mg

Registered Category: Chemicals Category 3

Marketing Authorization Holder/ Manufacturer: Jinzhou Avanc Pharmaceutical Co.,

Ltd.* (錦州奧鴻藥業有限責任公司)

Drug Approval Number: Guo Yao Zhun Zi H20263119

III. Research and Development of the Drug and Marketing Situation of Similar Drugs

The Drug is a chemical drug independently developed by the Group (i.e., the Company and its subsidiaries/units, the same below). As of December 2025, the Group has invested approximately RMB8.74 million (unaudited) in total in the research and development of the Drug at current stage.

According to the latest data of IQVIA CHPA[1], the sales of Norepinephrine Bitartrate Injections in China (excluding Hong Kong, Macau and Taiwan) in 2024 was approximately RMB1,811 million.

IV. Impact on the Listed Company and Risk Warning

This approval for marketing of the Drug will further enrich the product line of the Group.

Due to the industry characteristics of pharmaceutical products, the specific sales performance after the market launch of pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

22 January 2026

** For identification purposes only*

[1] Provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data cover the drug sales market of hospitals with more than 100 beds in China, the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.